Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Debt (2019 - 2025)

Historic Non-Current Debt for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $740.4 million.

  • BridgeBio Pharma's Non-Current Debt rose 6972.59% to $740.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $740.4 million, marking a year-over-year increase of 6972.59%. This contributed to the annual value of $738.9 million for FY2024, which is 6550.12% up from last year.
  • Per BridgeBio Pharma's latest filing, its Non-Current Debt stood at $740.4 million for Q3 2025, which was up 6972.59% from $738.9 million recorded in Q4 2024.
  • Over the past 5 years, BridgeBio Pharma's Non-Current Debt peaked at $740.4 million during Q3 2025, and registered a low of $90.8 million during Q1 2021.
  • For the 5-year period, BridgeBio Pharma's Non-Current Debt averaged around $410.8 million, with its median value being $434.7 million (2024).
  • Its Non-Current Debt has fluctuated over the past 5 years, first crashed by 178.97% in 2021, then soared by 37829.93% in 2022.
  • BridgeBio Pharma's Non-Current Debt (Quarter) stood at $430.8 million in 2021, then grew by 0.06% to $431.0 million in 2022, then grew by 3.59% to $446.4 million in 2023, then soared by 65.5% to $738.9 million in 2024, then grew by 0.2% to $740.4 million in 2025.
  • Its last three reported values are $740.4 million in Q3 2025, $738.9 million for Q4 2024, and $436.2 million during Q3 2024.